Literature DB >> 18197397

Aspirin resistance and diabetes mellitus.

R Ajjan1, R F Storey, P J Grant.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18197397     DOI： 10.1007/s00125-007-0898-3

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  43 in total

1.  Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy.

Authors:  J P Collet; D Park; C Lesty; J Soria; C Soria; G Montalescot; J W Weisel
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-05       Impact factor: 8.311

2.  Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers.

Authors:  P Fontana; S Nolli; G Reber; P de Moerloose
Journal:  J Thromb Haemost       Date:  2006-04       Impact factor: 5.824

Review 3.  Review article: gastrointestinal bleeding with low-dose aspirin - what's the risk?

Authors:  L Laine
Journal:  Aliment Pharmacol Ther       Date:  2006-09-15       Impact factor: 8.171

Review 4.  Coagulation and atherothrombotic disease.

Authors:  Ramzi Ajjan; Peter J Grant
Journal:  Atherosclerosis       Date:  2005-12-15       Impact factor: 5.162

Review 5.  The collagen-platelet interaction.

Authors:  M J Barnes; C G Knight; R W Farndale
Journal:  Curr Opin Hematol       Date:  1998-09       Impact factor: 3.284

6.  In vitro acetylation of plasma proteins, enzymes and DNA by aspirin.

Authors:  R N Pinckard; D Hawkins; R S Farr
Journal:  Nature       Date:  1968-07-06       Impact factor: 49.962

7.  Prevalence of aspirin resistance in patients with type 2 diabetes.

Authors:  S Fateh-Moghadam; U Plöckinger; N Cabeza; P Htun; T Reuter; S Ersel; M Gawaz; R Dietz; W Bocksch
Journal:  Acta Diabetol       Date:  2005-06       Impact factor: 4.280

8.  Acetylation of the NH2-terminal serine of prostaglandin synthetase by aspirin.

Authors:  G J Roth; C J Siok
Journal:  J Biol Chem       Date:  1978-06-10       Impact factor: 5.157

9.  Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid.

Authors:  S Williams; K Fatah; P Hjemdahl; M Blombäck
Journal:  Eur Heart J       Date:  1998-11       Impact factor: 29.983

10.  Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus.

Authors:  Sheena S Mehta; Robert J Silver; Arthur Aaronson; Martin Abrahamson; Allison B Goldfine
Journal:  Am J Cardiol       Date:  2006-01-06       Impact factor: 2.778
View more
  13 in total

Review 1.  Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis.

Authors:  Scot H Simpson; John-Michael Gamble; Laurie Mereu; Thane Chambers
Journal:  J Gen Intern Med       Date:  2011-06-07       Impact factor: 5.128

Review 2.  Reducing the risk of stroke in type 2 diabetes: pathophysiological and therapeutic perspectives.

Authors:  Dirk Sander; Mark T Kearney
Journal:  J Neurol       Date:  2009-04-29       Impact factor: 4.849

3.  Diabetes mellitus and cardiovascular prevention: the role and the limitations of currently available antiplatelet drugs.

Authors:  A Tufano; E Cimino; M N D Di Minno; P Ieranò; E Marrone; A Strazzullo; G Di Minno; A M Cerbone
Journal:  Int J Vasc Med       Date:  2011-06-30

4.  Risk management of risk management: Combining proton pump inhibitors with low-dose aspirin.

Authors:  Harald Vonkeman; Inger Meek; Mart van de Laar
Journal:  Drug Healthc Patient Saf       Date:  2010-10-06

5.  The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin.

Authors:  Søs Neergaard-Petersen; Anne-Mette Hvas; Erik Lerkevang Grove; Sanne Bøjet Larsen; Søren Gregersen; Steen Dalby Kristensen
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

6.  Evaluation of low-dose aspirin for primary prevention of ischemic stroke among patients with diabetes: a retrospective cohort study.

Authors:  Ye-Jee Kim; Nam-Kyong Choi; Mi-Sook Kim; Joongyub Lee; Yoosoo Chang; Jong-Mi Seong; Sun-Young Jung; Ju-Young Shin; Ji-Eun Park; Byung-Joo Park
Journal:  Diabetol Metab Syndr       Date:  2015-02-15       Impact factor: 3.320

7.  Establishing a predictive model for aspirin resistance in elderly Chinese patients with chronic cardiovascular disease.

Authors:  Jian Cao; Wei-Jun Hao; Ling-Gen Gao; Tian-Meng Chen; Lin Liu; Yu-Fa Sun; Guo-Liang Hu; Yi-Xin Hu; Li Fan
Journal:  J Geriatr Cardiol       Date:  2016-07       Impact factor: 3.327

8.  Effects of Post-Translational Modifications of Fibrinogen on Clot Formation, Clot Structure, and Fibrinolysis: A Systematic Review.

Authors:  Judith J de Vries; Charlotte J M Snoek; Dingeman C Rijken; Moniek P M de Maat
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-01-09       Impact factor: 8.311

Review 9.  Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials.

Authors:  Giorgia De Berardis; Michele Sacco; Giovanni F M Strippoli; Fabio Pellegrini; Giusi Graziano; Gianni Tognoni; Antonio Nicolucci
Journal:  BMJ       Date:  2009-11-06

10.  High glucose inhibits the aspirin-induced activation of the nitric oxide/cGMP/cGMP-dependent protein kinase pathway and does not affect the aspirin-induced inhibition of thromboxane synthesis in human platelets.

Authors:  Isabella Russo; Michela Viretto; Cristina Barale; Luigi Mattiello; Gabriella Doronzo; Andrea Pagliarino; Franco Cavalot; Mariella Trovati; Giovanni Anfossi
Journal:  Diabetes       Date:  2012-07-26       Impact factor: 9.461
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.